Related Experiment Videos
Echocardiographic studies of regression of left ventricular hypertrophy in hypertension
Insights
Certain antihypertensive drugs can reverse cardiac hypertrophy, reducing left ventricular mass. However, arteriolar vasodilators did not show this effect, highlighting varied drug impacts on heart structure.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Echocardiography enables precise measurement of left ventricular (LV) dimensions and mass.
- Understanding cardiac structural changes, particularly LV hypertrophy, has significantly advanced.
- Cardiac hypertrophy is recognized as a potentially reversible condition with specific therapies.
Purpose of the Study:
- To review the impact of various antihypertensive therapies on left ventricular mass.
- To identify which classes of antihypertensive drugs promote regression of cardiac hypertrophy.
- To explore the factors contributing to differential responses in LV hypertrophy among treatments.
Main Methods:
- Review of studies utilizing echocardiography to assess left ventricular wall thickness and mass.
- Analysis of therapeutic interventions involving different classes of antihypertensive medications.
- Comparison of changes in left ventricular mass following 8-12 weeks of treatment.
Main Results:
- Sympatholytics, ACE inhibitors, and calcium channel blockers effectively reduced left ventricular mass.
- Arteriolar vasodilators did not induce regression of hypertrophy, even with controlled blood pressure.
- Data on diuretics and beta-blockers regarding hypertrophy regression remain inconclusive.
Conclusions:
- The regression of left ventricular hypertrophy is achievable with specific antihypertensive agents.
- Drug-specific mechanisms, beyond blood pressure reduction, influence cardiac remodeling.
- Further research is needed to clarify the role of diuretics and beta-blockers in LV hypertrophy reversal.
Abstract:
The availability of echocardiography has allowed direct determinations of left ventricular wall thickness and calculation of left ventricular mass. As a result, the past decade has witnessed a remarkable evolution in our understanding of structural changes in the heart. Moreover, cardiac hypertrophy was found to be reversible by some forms of therapy. In general, reduction of left ventricular mass became evident after 8 to 12 weeks of antihypertensive therapy. Sympatholytics (including methyldopa and reserpine), converting enzyme inhibitors (captopril and enalapril), and calcium entry blockers led to significant regression of left ventricular hypertrophy. On the other hand, arteriolar vasodilators (hydralazine, trimazosin, and minoxidil) were not associated with regression of hypertrophy despite adequate blood pressure control. Finally, data regarding diuretics and beta-blockers are controversial. These differences in results among various antihypertensive drugs reflect the multiplicity of factors modulating left ventricular hypertrophy.